2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
7
Prostatic Neoplasms
5
Brain Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Radiation Injuries
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemangioma
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Scleroderma, Localized
1
Respiratory Distress Syndrome
1
Radiation Pneumonitis
1
Popliteal Cyst
1
Polycystic Ovary Syndrome
1
Pneumonia, Viral
1
Pneumonia
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Optic Neuritis
1
Neurodermatitis
1
Neoplastic Cells, Circulating
1
Neoplasms, Fibrous Tissue
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Interventions
Adalimumab
19
Etanercept
16
Methotrexate
11
Infliximab
8
tocilizumab
7
Rituximab
7
golimumab
6
Abatacept
6
tofacitinib
5
Tumor Necrosis Factor Inhibitors
5
olokizumab
4
Certolizumab Pegol
4
Antirheumatic Agents
3
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Arthritis, Rheumatoid
×
Adrenal Cortex Hormones
×
Clear all
NCT02046603
2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3
Completed
162 enrolled
30 charts